Understanding China's Biotech Ecosystem
An independent research and industry intelligence initiative covers China’s biotechnology ecosystem.
-
China has become one of the world's fastest-growing sources of biotech innovation, yet much of its ecosystem remains difficult for global audiences to navigate. Inside China connects the science, companies, clinical development, and industry trends shaping the next generation of biotechnology.
-
Frameworks to help global biotech companies identify the most appropriate pathway into China and the CROs, CDMOs, regulatory, clinical and other resources required at each stage.
-
mRNA Personalized Cancer Vaccines
A research series examining China's personalized cancer vaccine landscape—from neoantigen discovery and mRNA manufacturing to clinical development and commercialization.
-
Digging into the pipelines and evidence to understand the real value behind biotech deals.
Spotlight
-
![]()
From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?
Aiolos and Kailera show that the value of a China-to-global NewCo depends not only on the asset, but also on how the originator structures its rights. The key question is which future event—an acquisition, IPO, partnership, or commercialization—will create value, and whether the original biotech company is positioned to participate.
-
![]()
The Rise of China's Personalized Cancer Vaccine Ecosystem
Personalized cancer vaccines are emerging as one of China's most dynamic areas of biotechnology innovation. This ongoing research series explores the science, companies, clinical pipelines, manufacturing ecosystem, and commercialization landscape behind this rapidly evolving field.
-
![]()
Candid Therapeutics and UCB: When China-Origin Assets Become Global Strategy
Candid’s potential US$2.2 billion exit shows that the real value of China-origin biotech assets lies not in where they come from, but in how they are repositioned for the world.
-
![]()
mRNA Personalized Cancer Vaccine Mechanism
From neoantigen discovery to clinical development, manufacturing, and commercialization.
-
![]()
Why China Is Becoming More Important to Global Clinical Development
China’s clinical development ecosystem is advancing through regulatory reform, faster site activation, concentrated patient pools, and experienced investigators—not simply access to a large population. Well-designed IITs can generate early human data and validate mechanisms, biomarkers, and clinical sites, but they still need a clear path toward formal IND and registrational development.
What should we explore next?
Share companies, experts, investors, clinical resources, CDMOs, or questions you think we should cover.
Independent • Research-Led • Industry-Focused